Arctic Therapeutics utilizes bioinformatics and AI to analyze genetic sequencing, mapping the genetic causes of diseases to develop targeted treatments. This approach significantly reduces the risks, costs, and time associated with traditional drug development, enabling faster access to effective therapies for patients.
Funding
$27.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development for complex diseases is slow, expensive, and carries high risks due to the difficulty in identifying the precise genetic causes and developing targeted treatments. This often results in delayed access to effective therapies for patients suffering from diseases like dementia, Alzheimer’s, autoimmune disorders, and inflammatory conditions.
Solution
Arctic Therapeutics utilizes a genomics-driven approach, augmented by bioinformatics and AI, to accelerate and de-risk drug development. By analyzing genetic sequencing data and mapping the genetic causes of diseases at a granular level, Arctic Therapeutics develops targeted therapies with increased precision. The company leverages a nationwide genealogy database, a biobank licensed by the Icelandic Ministry of Health, and partnerships with national hospitals providing encrypted access to national Electronic Health Records (EHR) to enhance its research and development. This approach aims to reduce the time and cost associated with traditional drug development, while increasing the likelihood of bringing effective treatments to patients.
Target Audience
The primary target audience includes patients suffering from genetically-linked diseases such as Alzheimer’s, dementia, autoimmune disorders, inflammatory conditions, and severe asthma, as well as pharmaceutical companies seeking to in-license de-risked drug candidates.
Features
- AI-driven analysis of genetic sequencing data to identify disease-causing genes and therapeutic targets.
- Development of targeted therapies for diseases like familial dementia, Alzheimer’s, inflammatory skin diseases, autoimmune diseases, and severe asthma.
- AT-001: A drug designed for the treatment and prevention of cerebral amyloid angiopathy (CAA) and dementia by blocking amyloid aggregation.
- AT-004: A topical cream for treating inflammatory skin diseases such as acne vulgaris and atopic dermatitis, utilizing a non-neuronal cholinergic system mechanism.
- AT-003: A mitophagy/autophagy modulator designed for the treatment of autoimmune and inflammatory diseases.
- AT-005: An siRNA-based drug delivered by inhalation to treat severe asthma by targeting the cellular binding site for rhinovirus.
- Clinically-certified genotyping and sequencing facility.